Literature DB >> 23010705

Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma.

Lisa M Sutton1, Dengfeng Cao, Venetia Sarode, Kyle H Molberg, Kwame Torgbe, Barbara Haley, Yan Peng.   

Abstract

To characterize prognostic values of androgen receptor (AR) in triple-negative (TN) breast cancers, we investigated AR expression status and levels, explored an association of AR expression with metastatic disease, and correlated AR expression with Ki-67 in TN invasive breast carcinomas. AR expression was analyzed with immunohistochemistry in 121 cases of TN tumors. Thirty-nine cases had distant metastatic disease and 82 had locoregional disease only. AR was positive in 38 (31.4%) of the 121 cases. Our results indicate that among the AR-positive TN tumors, distant metastases are significantly associated with lower expression of AR compared with cases with only locoregional disease, and that AR expression negatively correlates with Ki-67 expression. These findings suggest that decreased intratumoral AR expression may be predictive of distant metastatic disease and AR expression levels may have potential prognostic value in AR-expressing TN tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010705     DOI: 10.1309/AJCP8AVF8FDPTZLH

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  31 in total

Review 1.  Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

Authors:  Tessa G Steenbruggen; Mette S van Ramshorst; Marleen Kok; Sabine C Linn; Carolien H Smorenburg; Gabe S Sonke
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

Review 2.  Role of the androgen receptor in triple-negative breast cancer.

Authors:  Murtuza Rampurwala; Kari B Wisinski; Ruth O'Regan
Journal:  Clin Adv Hematol Oncol       Date:  2016-03

3.  Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study.

Authors:  Ya-Xuan Liu; Ke-Jing Zhang; Li-Li Tang
Journal:  Oncol Lett       Date:  2018-04-20       Impact factor: 2.967

4.  Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?

Authors:  Damoun Safarpour; Shabnam Pakneshan; Fattaneh A Tavassoli
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

Review 5.  Emerging therapeutic targets in metastatic progression: A focus on breast cancer.

Authors:  Zhuo Li; Yibin Kang
Journal:  Pharmacol Ther       Date:  2016-03-19       Impact factor: 12.310

6.  Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.

Authors:  Gilda Schmidt; Christoph Gerlinger; Ingolf Juhasz-Böss; Elmar Stickeler; Achim Rody; Cornelia Liedtke; Pauline Wimberger; Theresa Link; Eberhard Müller; Tanja Fehm; Manuela Abel; Stefan Stein; Rainer Bohle; Jan Endrikat; Erich-Franz Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-23       Impact factor: 4.553

7.  Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.

Authors:  Tarah M Regan Anderson; Shihong Ma; Carlos Perez Kerkvliet; Yan Peng; Taylor M Helle; Raisa I Krutilina; Ganesh V Raj; John A Cidlowski; Julie H Ostrander; Kathryn L Schwertfeger; Tiffany N Seagroves; Carol A Lange
Journal:  Mol Cancer Res       Date:  2018-07-10       Impact factor: 5.852

Review 8.  Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis.

Authors:  Li Zhang; Cheng Fang; Xianqun Xu; Anling Li; Qing Cai; Xinghua Long
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

9.  The impact of IGF-1R expression on the outcomes of patients with breast cancer: a meta-analysis.

Authors:  Shunchao Yan; Xin Jiao; Kai Li; Wusheng Li; Huawei Zou
Journal:  Onco Targets Ther       Date:  2015-01-29       Impact factor: 4.147

10.  Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.

Authors:  Pierluigi Gasparini; Matteo Fassan; Luciano Cascione; Gulnur Guler; Serdar Balci; Cigdem Irkkan; Carolyn Paisie; Francesca Lovat; Carl Morrison; Jianying Zhang; Aldo Scarpa; Carlo M Croce; Charles L Shapiro; Kay Huebner
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.